Case Reports
doi: 10.1016/s0885-3924(01)00367-0.
Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients
Affiliations
- PMID: 11779672
- DOI: 10.1016/s0885-3924(01)00367-0
Item in Clipboard
Case Reports
Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients
J Pain Symptom Manage.
2002 Jan.
Free article
Abstract
Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide. The underlying causes of dyspnea varied. Twenty milligrams of furosemide was nebulized and inhaled four times each day. Dyspnea dramatically improved and could be controlled for weeks. No noticeable side effects were observed. Inhalation of nebulized furosemide seems to be an effective and useful treatment for dyspnea in terminal cancer patients, but these observations need to be confirmed in a randomized controlled trial.
Comment in
-
Re: nebulized furosemide for dyspnea in terminal cancer patients.J Pain Symptom Manage. 2002 Sep;24(3):274-5; author reply 275-6. doi: 10.1016/s0885-3924(02)00479-7. J Pain Symptom Manage. 2002. PMID: 12458098 Clinical Trial. No abstract available.
Similar articles
-
Effect of nebulized furosemide in terminally ill cancer patients with dyspnea.J Pain Symptom Manage. 2003 Oct;26(4):962-7. doi: 10.1016/s0885-3924(03)00322-1. J Pain Symptom Manage. 2003. PMID: 14575057
-
Re: nebulized furosemide for dyspnea in terminal cancer patients.J Pain Symptom Manage. 2002 Sep;24(3):274-5; author reply 275-6. doi: 10.1016/s0885-3924(02)00479-7. J Pain Symptom Manage. 2002. PMID: 12458098 Clinical Trial. No abstract available.
-
Nebulized furosemide for the management of dyspnea: does the evidence support its use?J Pain Symptom Manage. 2008 Oct;36(4):424-41. doi: 10.1016/j.jpainsymman.2007.10.017. Epub 2008 May 12. J Pain Symptom Manage. 2008. PMID: 18468839 Review.
-
Nebulized frusemide for dyspnoea.Palliat Med. 1994;8(3):258. doi: 10.1177/026921639400800315. Palliat Med. 1994. PMID: 7952379 No abstract available.
-
Nebulized opioids for the palliation of dyspnea in terminally ill patients.Am J Health Syst Pharm. 2017 Jul 15;74(14):1053-1061. doi: 10.2146/ajhp150893. Am J Health Syst Pharm. 2017. PMID: 28687551 Review.
Cited by
-
Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.Lung. 2020 Feb;198(1):113-120. doi: 10.1007/s00408-019-00292-7. Epub 2019 Nov 15. Lung. 2020. PMID: 31728632 Free PMC article. Clinical Trial.
-
The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double blind randomized, clinical trial.Emerg Med Int. 2014;2014:638102. doi: 10.1155/2014/638102. Epub 2014 Apr 27. Emerg Med Int. 2014. PMID: 24876968 Free PMC article.
-
Dyspnea review for the palliative care professional: treatment goals and therapeutic options.J Palliat Med. 2012 Jan;15(1):106-14. doi: 10.1089/jpm.2011.0110. J Palliat Med. 2012. PMID: 22268406 Free PMC article. Review.
-
An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide.BMC Palliat Care. 2012 Apr 30;11:6. doi: 10.1186/1472-684X-11-6. BMC Palliat Care. 2012. PMID: 22546176 Free PMC article.
-
Management of Breathlessness in Palliative Care: Inhalers and Dyspnea-A Literature Review.Rambam Maimonides Med J. 2019 Jan 28;10(1):e0006. doi: 10.5041/RMMJ.10357. Rambam Maimonides Med J. 2019. PMID: 30332384 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
